Scott-McKean Jonah J, Wenger Galen R, Tecott Laurence H, Costa Alberto C S
Neuroscience Training Program, University of Colorado Denver, Aurora, CO, USA.
Open Neuropsychopharmacol J. 2008 Jan 1;1:24-32. doi: 10.2174/1876523800801010024.
Over the last two decades, our ever-increasing ability to manipulate the mouse genome has resulted in a variety of genetically defined mouse models of depression and other psychiatric and neurological disorders. However, it is still the case that some relevant rodent models for depression and antidepressant action have been validated experimentally in rats only and not in mice. An important example of such models is the operant model of antidepressant action known as differential-reinforcement-of-low-rates 72-second (DRL 72-s). A specific set of drug-induced changes on the performance of rats responding under a DRL 72-s schedule of reinforcement has been shown to be a highly reliable predictor of antidepressant activity in human depressive disorders. The aim of this study is to validate the use of the DRL 72-s schedule in mice by both genetic and pharmacological means. We have analyzed the actions of the specific serotonin reuptake inhibitor (SSRI) fluoxetine and the tricyclic agent desipramine (DMI) on wild-type and 5-hydroxytryptamine 1A receptor-null mutant (5-HT(1A)R KO) mice. In agreement with the literature on rats, we found that fluoxetine produced an acute antidepressant-like effect in 5-HT(1A)R KO mice but not in wild-type (Wt) mice. Additionally, an antidepressant-like effect was observed when DMI was administered to both 5-HT(1A)R KO and Wt mice. In conclusion: through the use of both genetic and pharmacological strategies, this study validates the extension of a protocol involving the DRL 72-s operant schedule of reinforcement as a behavioral model for the action of antidepressants in mice.
在过去二十年中,我们操控小鼠基因组的能力不断提高,已产生了多种针对抑郁症以及其他精神和神经疾病的基因定义小鼠模型。然而,仍有一些用于抑郁症和抗抑郁作用的相关啮齿动物模型仅在大鼠中通过实验验证,而未在小鼠中验证。此类模型的一个重要例子是称为低速率72秒差异强化(DRL 72 - s)的抗抑郁作用操作性模型。一组特定的药物诱导的对在DRL 72 - s强化程序下做出反应的大鼠行为表现的改变,已被证明是人类抑郁症中抗抑郁活性的高度可靠预测指标。本研究的目的是通过基因和药理学方法验证DRL 72 - s程序在小鼠中的应用。我们分析了特异性5-羟色胺再摄取抑制剂(SSRI)氟西汀和三环类药物地昔帕明(DMI)对野生型和5-羟色胺1A受体基因敲除突变体(5-HT(1A)R KO)小鼠的作用。与关于大鼠的文献一致,我们发现氟西汀在5-HT(1A)R KO小鼠中产生了急性抗抑郁样效应,但在野生型(Wt)小鼠中未产生。此外,当DMI给予5-HT(1A)R KO和Wt小鼠时均观察到了抗抑郁样效应。总之:通过使用基因和药理学策略,本研究验证了将涉及DRL 72 - s操作性强化程序的方案扩展为小鼠抗抑郁作用行为模型的可行性。